European Archives of Psychiatry and Clinical Neuroscience

, Volume 251, Issue 2, pp 57–59

Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report

Authors

  • A. Suzuki
    • Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • T. Kondo
    • Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • K. Mihara
    • Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • N. Yasui-Furukori
    • Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • K. Otani
    • Department of Neuropsychiatry, Yamagata University School of Medicine, Yamagata, Japan
  • H. Furukori
    • Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • S. Kaneko
    • Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki 036-8562, Japan, e-mail: kon@cc.hirosaki-u.ac.jp
  • Y. Inoue
    • Pharmaceutical Technology Center, Yoshitomi Pharmaceutical Industries Ltd., Fukuoka, Japan
Original paper

DOI: 10.1007/s004060170053

Cite this article as:
Suzuki, A., Kondo, T., Mihara, K. et al. European Archives of Psychiatry and Clinical Neurosciences (2001) 251: 57. doi:10.1007/s004060170053

Abstract

The relationship between TaqI A dopamine D2 receptor (DRD2) polymorphism and therapeutic response to bromperidol, a selective dopamine antagonist, was investigated in 30 acutely exacerbated schizophrenic inpatients. Patients were treated with bromperidol 6–18 mg/day for 3 weeks. Clinical symptoms were evaluated by the Brief Psychiatric Rating Scale (BPRS) before and 3 weeks after the treatment. The TaqI A genotypes were determined with the PCR method. There was no significant difference in the percentage improvement of total BPRS or 5-subgrouped symptoms (positive, negative, anxiety-depression, excitement and cognitive symptoms) after the 3-week treatment between the patients with A1 alleles (n=18) and those with no A1 allele (n=12). Although the present study is preliminary, it is suggested that the TaqI A DRD2 polymorphism is not associated with therapeutic response to bromperidol in schizophrenic patients.

Key words BromperidolSchizophreniaTaqI A DRD2 polymorphismTherapeutic response

Copyright information

© Steinkopff Verlag 2001